By Admin at 1 Jun 2016

In 2014, the FDA approved the immunotherapy drug pembrolizumab (brand name Keytruda®) for people with melanoma that cannot be removed by surgery or that has spread to other parts of the body. The drug was approved under an accelerated fast-track process because of positive initial results from a clinical trial. The end results of that study have now been released and confirm the drug’s promise for late-stage melanoma patients.